Exelixis/$EXEL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Exelixis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Ticker

$EXEL
Primary listing

Industry

Biotechnology

Employees

1,147

Exelixis Metrics

BasicAdvanced
$12B
20.32
$2.20
0.28
-

What the Analysts think about Exelixis

Analyst ratings (Buy, Hold, Sell) for Exelixis stock.

Bulls say / Bears say

Exelixis' late-stage STELLAR-303 study demonstrated a statistically significant improvement in overall survival for patients treated with zanzalintinib in combination with Tecentriq, increasing the likelihood of regulatory approval. (nasdaq.com)
The company has entered into a clinical development collaboration with Merck to evaluate zanzalintinib in combination with KEYTRUDA and WELIREG, potentially expanding its oncology portfolio. (stocktitan.net)
BTIG initiated coverage of Exelixis with a 'Buy' recommendation, reflecting confidence in the company's growth prospects. (nasdaq.com)
Barclays analyst Peter Lawson maintained a 'Hold' rating on Exelixis, indicating a cautious outlook on the stock's near-term performance. (markets.businessinsider.com)
Institutional investors like Amundi have reduced their holdings in Exelixis, which could signal concerns about the company's future performance. (defenseworld.net)
Exelixis reported a decrease in quarterly revenue and net profit compared to the previous year, raising concerns about its financial health. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Exelixis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Exelixis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EXEL

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs